AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Monika Tjia
After hitting a high on Dec. 19, IDEC Pharmaceuticals slid 58%. Since then it's worked its way back up, sitting 16% off its high.
In the past nine weeks, its Relative Price Strength Rating has improved to 91 from 55. Its Relative Strength line is up, a good sign.
The San Diego-based firm develops drugs to treat cancer and autoimmune diseases. The firm's most popular drug is Rituxan, which is used to treat non-Hodgkin's lymphoma.
Profit growth has climbed in the past two quarters, from 43% to 140% to 500%. Analysts predict fiscal 2001 earnings will rise 50% vs. a 24% rise in 2000, says First Call.
Of the 255 stocks in the Medical-Biomed/Genetics group, IDEC and Qiagen NV have the highest Earnings Per Share Ratings at 99.
Sales growth ...